Agilent Technologies Inc. (NYSE: A), a worldwide provider of cancer diagnostics through its Dako Pathology Solutions division, today announced that it has published "Breast Cancer Diagnosis: Past, Present and Future," a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
The white paper was made available at a gathering of the United States and Canadian Academy of Pathology under way this week in Seattle.
"Agilent is committed to providing industry-leading educational resources to our customers, and we are particularly excited about this publication," said Hans Christian Pedersen, head of Companion Diagnostics and IHC reagents, Global Marketing, Agilent. "It provides pathologists with a comprehensive resource for the diagnosis of breast cancers."
An overview of best practices, the paper was written by doctors Ping Tang and David G. Hicks of the University of Rochester in New York and Christine Desmedt of the Jules Bordet Institute in Brussels.
The 51-page paper reviews how the understanding of breast cancer has evolved and how researchers have established clinically meaningful biomarkers and ancillary tests. It also discusses the potential (and possible pitfalls) of applying these biomarkers in diagnosing breast cancer and planning treatment.
"By uniting morphological, immunohistochemical and molecular methods, pathologists can provide a comprehensive diagnosis that supports individualized therapy for breast cancer patients," said Dr. Ping Tang, one of the co-authors from Rochester. "By covering useful antibodies and molecular tests in one comprehensive source, we think this article will be a valuable educational resource for breast pathologists."